Dr. Michael D. Geschwind, MD, PhD

Dr. Geschwind practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Geschwind's NPI, 1700813565, was assigned on June 27, 2006. Dr. Geschwind graduated from Albert Einstein College of Medicine in 1996. Dr. Geschwind holds California license A73472.

Dr. Geschwind's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Geschwind's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Geschwind to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Geschwind practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Geschwind's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Geschwind's licenses on file in 2 states: California and Florida.

Dmand AI lists alzheimer's disease, hypersomnia and non-alzheimer's dementia (chronic) among the conditions Dr. Geschwind treats.

CMS data shows 116 Medicare services from Dr. Geschwind across 2 procedure codes in 2024, for 16 Medicare patients. Medicare paid $4,862 for them. Every service was in an office.

CMS counts 16 Medicare patients who saw Dr. Geschwind in 2024. 75% of them have high cholesterol. Their average risk score is 1.35, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Geschwind's median patient age at 57, with 58% women.

In 2024, Dr. Geschwind wrote 34 Medicare Part D claims. 76% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $36,629 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Geschwind for performance year 2024, reported as part of a group. Dr. Geschwind accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Geschwind as offering telehealth.

Dmand AI links 118 papers to Dr. Geschwind, published from 2006 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Creutzfeldt-Jakob Syndrome, Brain and Magnetic Resonance Imaging. Dr. Geschwind has published most often in Arch Neurol. Dr. Geschwind's most frequent co-authors are Bruce L. Miller, MD, Stephen J. Dearmond, MD and Jeffrey Marc Gelfand, MD.

Dmand AI links Dr. Geschwind to 12 clinical trials, 3 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Huntington Disease, Chorea and Spinocerebellar Ataxias. Biohaven Pharmaceuticals, Inc. sponsors the most, 2.

CMS Open Payments shows 28 general payments to Dr. Geschwind from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. Eli Lilly and Company paid the most, $22,282.

Dmand AI lists 1 award for Dr. Geschwind, most recently CMS Stage 1 EHR in 2013.

Dr. Geschwind graduated from Albert Einstein College of Medicine in 1996.

Dr. Geschwind is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.